The Discounted Cash Flow (DCF) valuation of Adaptimmune Therapeutics PLC (ADAP) is (127.92) USD. With the latest stock price at 0.28 USD, the upside of Adaptimmune Therapeutics PLC based on DCF is -45770.6%.
Based on the latest price of 0.28 USD and our DCF valuation, Adaptimmune Therapeutics PLC (ADAP) is a sell. selling ADAP stocks now will result in a potential gain of 45770.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 7.0% - 8.8% | 7.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (248.72) - (86.82) | (127.92) |
| Upside | -88896.4% - -31095.5% | -45770.6% |